PubRank

Ross L Levine

Author PubWeight™ 297.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The landscape of somatic copy-number alteration across human cancers. Nature 2010 31.88
2 Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010 15.20
3 The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010 13.13
4 Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012 10.20
5 Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011 9.90
6 JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007 8.18
7 IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012 7.95
8 MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006 7.95
9 Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011 7.37
10 MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006 5.95
11 A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011 5.78
12 Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009 5.72
13 The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012 4.97
14 Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006 4.63
15 Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007 4.52
16 Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012 4.41
17 Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006 3.88
18 The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005 3.47
19 Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012 3.33
20 High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008 3.30
21 Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007 3.23
22 EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013 3.13
23 A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009 3.10
24 Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005 2.94
25 Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012 2.92
26 Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012 2.86
27 Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008 2.80
28 TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J 2013 2.70
29 Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 2012 2.69
30 Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010 2.69
31 Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012 2.64
32 JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011 2.56
33 ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012 2.42
34 Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013 2.38
35 Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012 2.28
36 Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012 2.19
37 The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell 2010 2.09
38 HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010 1.93
39 Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009 1.89
40 Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nat Med 2013 1.89
41 TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011 1.87
42 PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 2010 1.82
43 TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 2013 1.81
44 A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A 2010 1.81
45 The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 2012 1.79
46 Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood 2009 1.78
47 FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007 1.74
48 Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 2013 1.71
49 Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013 1.71
50 Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003 1.69
51 Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009 1.69
52 Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood 2014 1.68
53 Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012 1.65
54 High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2008 1.64
55 Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 2012 1.62
56 Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012 1.46
57 The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 2005 1.45
58 The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest 2009 1.44
59 Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010 1.42
60 JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 2006 1.41
61 Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013 1.41
62 Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013 1.37
63 Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med 2013 1.36
64 Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013 1.33
65 Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 2013 1.27
66 Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov 2014 1.25
67 A common genetic mechanism in malignant bone marrow diseases. N Engl J Med 2009 1.23
68 Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006 1.16
69 Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med 2015 1.15
70 Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. J Clin Invest 2013 1.12
71 A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A 2009 1.12
72 JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci 2012 1.08
73 Metabolism and the leukemic stem cell. J Exp Med 2010 1.08
74 A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol 2012 1.07
75 Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol 2008 1.05
76 Potential biomarkers for the diagnosis of stroke. Expert Rev Cardiovasc Ther 2009 1.03
77 Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood 2011 1.02
78 Molecular biology of myelodysplastic syndromes. Semin Oncol 2011 1.01
79 Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am 2011 1.01
80 Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013 1.01
81 Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006 1.01
82 Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 2014 0.99
83 Genetics of myeloproliferative neoplasms. Cancer J 2014 0.98
84 CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012 0.96
85 HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 2013 0.94
86 Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest 2014 0.94
87 New pieces of a puzzle: the current biological picture of MPN. Biochim Biophys Acta 2012 0.93
88 Reperfusion seizures: a manifestation of cerebral reperfusion injury after administration of recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis 2007 0.92
89 Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood 2010 0.92
90 Do circulating tumor cells play a role in coagulation and thrombosis? Front Oncol 2012 0.92
91 The interface between stroke and infectious disease: infectious diseases leading to stroke and infections complicating stroke. Curr Neurol Neurosci Rep 2009 0.92
92 ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica 2010 0.91
93 How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program 2012 0.90
94 Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol 2010 0.88
95 HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest 2014 0.88
96 Normal IQ in a 55-year-old with newly diagnosed rhombencephalosynapsis. Arch Clin Neuropsychol 2005 0.88
97 Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Curr Opin Oncol 2007 0.87
98 Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res 2012 0.86
99 Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am 2012 0.86
100 LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 2008 0.85
101 Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Int J Hematol 2013 0.84
102 Recent advances in the treatment of acute myeloid leukemia. F1000 Med Rep 2010 0.82
103 The role of mutations in epigenetic regulators in myeloid malignancies. Immunol Rev 2015 0.82
104 JAK2 and MPL mutations in myeloproliferative neoplasms. Acta Haematol 2008 0.82
105 Leveraging cancer genome information in hematologic malignancies. J Clin Oncol 2013 0.82
106 Targeting β-catenin in CML: leukemia stem cells beware! Cell Stem Cell 2012 0.81
107 Inherited susceptibility to pediatric acute lymphoblastic leukemia. Nat Genet 2009 0.81
108 IDH1 mutations disrupt blood, brain, and barriers. Cancer Cell 2012 0.80
109 Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells. Phys Biol 2013 0.79
110 Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. Am J Hematol 2013 0.79
111 Nuclear JAK2. Blood 2011 0.78
112 Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. Biol Blood Marrow Transplant 2009 0.78
113 Utilization of self-expanding stents in the treatment of intracranial atherosclerotic disease in the distal small cerebral vessels. Neuroradiology 2007 0.78
114 Advances in the development of animal models of myeloid leukemias. Semin Hematol 2013 0.77
115 Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models. J Clin Invest 2011 0.76
116 JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target? Ther Adv Hematol 2011 0.76
117 Metabolic syndromes and malignant transformation: where the twain shall meet. Sci Transl Med 2010 0.76
118 A WIMSical approach to decoding DNA methylation in myeloid leukemia. Genome Biol 2014 0.75
119 Mining the epigenetic landscape in ALL. Nat Genet 2013 0.75
120 Stem Cells and Aging: What's Next? Cell Stem Cell 2015 0.75
121 Targeted immunotherapy for hairy cell leukemia. J Clin Oncol 2012 0.75
122 Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia. Acta Haematol 2012 0.75